Construction method and application of targeting hepatoma oncolytic adenovirus
An oncolytic adenovirus and a construction method are applied in the field of construction and application of an adenovirus vector GD55 carrying a GP73 promoter targeting liver cancer, which can solve the problems of low cure rate, high recurrence rate and mortality rate, poor prognosis, etc. Ease of grasp, tumor growth inhibition, and safety-enhancing effects
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0060] Background transcription of embodiment 1, GP73 and AFP gene in different cell lines
[0061] Related primers:
[0062] GP73 gene primers:
[0063] Sense: GGATGTCCTCCAGTTTCAGA;
[0064] Anti-sense: TTCTCCCACTTCCTTGTCAC
[0065] AFP gene primers:
[0066] Sense: CTTACACAAAGAAAAGCCCC
[0067] Anti-sense: GTCCGATAATAATGTCAGCC
[0068] GAPDH gene primers:
[0069] Sense: ATTCCACGGCACAGTCAAGG
[0070] Anti-sense: ACATACTCAGCACCAGCATCG
[0071] The total RNA of normal liver cells QSG-7701 and liver cancer cells SMMC-7721, Huh7, and Hep3B in the logarithmic growth phase was extracted by TRIZOL method, and reverse-transcribed into cDNA. - The relative expression of AFP and GP73 was obtained by PCR.
[0072] details as follows:
[0073] Note: The Q-PCR reaction system and reaction conditions are:
[0074]
[0075] Put the loaded eight-tube tube into the ABI7300 fluorescent quantitative PCR instrument, set the Q-PCR program, and the cycle conditions are:
[0076] ...
Embodiment 2
[0080] Example 2, Evaluation of the activity of the novel GP73 promoter in cells
[0081] The reporter gene plasmid phRL-TK was purchased from Promega Company, expressing Renilla luciferase under the control of the TK promoter; the plasmids pGL3-Basic (without promoter and enhancer) and pGL3-Control (with SV40 promoter) was purchased from Promega Company.
[0082] 1) Related plasmid construction
[0083] First design the following primers:
[0084] p-19: (Hind III) ACT AAGCTT CCGGCCTCCGCAGCGGCAAG
[0085] p-2616:(MluI)CG ACGCGT TAGTCCCACCACTCTCGA
[0086] p-413:(MluI)CG ACGCGT ATAAAGAAGGTAACGTGA
[0087] p-613:(MluI)CG ACGCGT GAATCTTCACTTTTTCCGTTG
[0088] p-677:(MluI)CG ACGCGT TCATCTGAGGCGCTGTTTCA
[0089] p-729:(MluI)TG ACGCGT CTCCGGGAGGTACGGCCTCA
[0090] Remarks: The underline represents the enzyme cleavage site.
[0091] Using the specific primers p-19:(Hind III) and p-2616:(MluI) at both ends of the above-mentioned GP73 promoter, using the total ...
Embodiment 3
[0104] Example 3. Construction of dual-targeted liver cancer oncolytic adenovirus
[0105] 1) Construction of related plasmids (underlined are the sequences of restriction sites listed)
[0106] p-19:(SnaB I)TAG TACGTA CCGGCCTCCGCAGCGGCAAG
[0107] p-677:(Xho I)CG CTCGAG TCATCTGAGGCGCTGTTTC
[0108] GM-CSF (sense): (Hind III) CC AAGCTT ATGTGGCTGCAGAGCCTGCT
[0109] GM-CSF (Anti-sense): (BamH I) AT GGATCC TCACTCCTGGACTGGCTC
[0110] mGM-CSF (sense): (Hind III) CCC AAGCTT ATGTGGCTGCAGAATTTAC
[0111] mGM-CSF (Anti-sense): (BamH I) CG GGATCC TCATTTTTGGCCTGGTT
[0112] EGFP (sense): (BamHI) AT GGATCC ATGGTGAGCAAGGGCGAGGAG
[0113] EGFP (antisense): (HindIII) CCT AAGCTT TTATCTAGATCCGGTGGATC
[0114] Using the total genomic RNA extracted from the peripheral blood of healthy people as a template, cDNA was amplified by RT-PCR, and the GM-CSF gene was obtained by PCR with GM-CSF upstream and downstream primers. The PCR reaction system was:
[0115]
[0116] The PC...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com